SYFOVRE Drug Patent Profile

When do Syfovre patents expire, and when can generic versions of Syfovre launch?

Syfovre is a drug marketed by Apellis Pharms and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and three patent family members in thirty countries.

The generic ingredient in SYFOVRE is pegcetacoplan. One supplier is listed for this compound. Additional details are available on the pegcetacoplan profile page.

DrugPatentWatch^® Generic Entry Outlook for Syfovre

Syfovre was eligible for patent challenges on May 14, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 15, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SYFOVRE

International Patents:	203
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	4
Drug Prices:	Drug price information for SYFOVRE
What excipients (inactive ingredients) are in SYFOVRE?	SYFOVRE excipients list
DailyMed Link:	SYFOVRE at DailyMed

See drug prices for SYFOVRE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYFOVRE

NDA:

217171

Dosage:

SOLUTION;INTRAVITREAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SYFOVRE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Apellis Pharmaceuticals, Inc.	PHASE3
AbbVie	PHASE1
Hoffmann-La Roche	PHASE1

See all SYFOVRE clinical trials

Pharmacology for SYFOVRE

Drug Class	Complement Inhibitor
Mechanism of Action	Complement Inhibitors

US Patents and Regulatory Information for SYFOVRE

SYFOVRE is protected by sixteen US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes				Y
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes				Y
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes			Y
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023		RX	Yes	Yes				Y

EU/EMA Drug Approvals for SYFOVRE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Swedish Orphan Biovitrum AB (publ)	Aspaveli	pegcetacoplan	EMEA/H/C/005553Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.	Authorised	no	no	yes	2021-12-13

International Patents for SYFOVRE

When does loss-of-exclusivity occur for SYFOVRE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYFOVRE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013344462
Australia	2018247243
Australia	2020260435
Australia	2023200929
Australia	2025201748
Brazil	112015011244
Canada	2891673

Supplementary Protection Certificates for SYFOVRE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3660033	301178	Netherlands		PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211214
3660033	PA2022010	Lithuania		PRODUCT NAME: PEGCETACOPLANAS ; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033	2022C/522	Belgium		PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
3660033	CA 2022 00023	Denmark		PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214
3660033	LUC00265	Luxembourg		PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214
3660033	122022000034	Germany		PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211213
3660033	2290021-1	Sweden		RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; DEN 2025-03-07 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.

SYFOVRE (pegcetacoplan) market dynamics and financial trajectory: sales outlook, pricing pressure, payer coverage, and exclusivity risk

Last updated: June 17, 2026

SYFOVRE (pegcetacoplan, administered via intravitreal injection) is the category’s leading late-stage complement C3-targeted therapy for geographic atrophy (GA) in age-related macular degeneration. Near-term financial trajectory is driven by (1) uptake among ophthalmology practices and retina subspecialists, (2) payer authorization patterns tied to trial-driven eligibility criteria, (3) ongoing real-world tolerability and treatment persistence, and (4) competitive timing against other complement-pathway and retinal late-stage pipeline programs. Downside risk is concentrated in reimbursement and channel mix, not manufacturing constraints, as the commercial ramp is primarily a demand-creation and access problem.

---

What is SYFOVRE and how does it monetize in geographic atrophy?

Pegcetacoplan is a C3 inhibitor designed for intravitreal administration in GA. The monetization model is typical for chronic retinal injectables: recurring dosing, adherence to eligibility criteria, and payer authorization that tracks disease stage and treatment response.

Core commercial drivers for a chronic intravitreal product

• Practice adoption: Retina specialists must build patient selection workflows and injection capacity.
• Patient persistence: Continued injections are required; discontinuation hits revenue immediately.
• Reimbursement friction: The product’s net price depends on prior authorization success and the ability to obtain coverage at launch and during renewals.
• Utilization controls: Payers often require documentation of baseline lesion size/phenotype aligned to label indications.

Key GA market structure

• High addressable population but fragmented care delivery: Treatment is delivered through retina clinics rather than integrated specialty pharmacy models.
• Local payer policy variance: Coverage terms can differ materially by health plan and region, shaping regional revenue concentration and discounting.

---

How are sales and revenue trending for SYFOVRE since launch?

SYFOVRE’s financial trajectory is best understood as a ramp with steep early adoption constraints that typically moderate after initial payer and site-of-care stabilization.

Ramping dynamics you should model

• Launch year shape: Early sales tend to be bounded by (a) payer approvals and (b) clinic onboarding.
• Quarterly volatility: Gains can pause when payers tighten documentation requirements or when competing products trigger formulary placement shifts.
• Patient funnel: Revenue growth is a function of new starts minus discontinuations, not simply new prescriptions.

What to track in earnings and distributor channels

• New patient starts per quarter
• Treatment persistence
• Average selling price and discount rate
• Geographic and payer mix
• Injection frequency adherence

(Commercial trend numbers are not provided in the input data, so this section focuses on dynamics that directly determine the financial curve.)

---

What market dynamics are pressuring SYFOVRE pricing and net revenue?

Pricing pressure for retinal injectables usually comes from payer benefit design and negotiated discounts rather than headline list price cuts. For SYFOVRE, the main levers are authorization policy, site-of-care dynamics, and the emergence of alternative GA therapies.

Payer coverage and prior authorization behavior

• Eligibility alignment: Plans prefer documentation that matches label entry criteria.
• Renewal hurdles: Continuation may be contingent on perceived clinical benefit.
• Utilization review: Payers can impose step edits or limit early to certain lesion characteristics.

Site-of-care economics

• Net revenue is sensitive to administration channel and how costs are allocated between pharmacy benefit, medical benefit, and buy-and-bill arrangements.

Competition-driven discounting

• When second or third entrants reach formulary pathways, discounts typically rise quickly even before large market share transfers occur.

---

Which competitors threaten SYFOVRE’s share in GA, and how does timing matter?

SYFOVRE is exposed to competitive displacement from other complement pathway inhibitors and alternative GA neuroprotective and anti-inflammatory strategies entering late-stage review and commercialization.

Competitive scenarios that affect the financial trajectory

1. Substitute with similar efficacy and easier access
   • Net price declines as payers compare total cost and authorization difficulty.
2. Efficacy differentiation
   • If clinical benefit in key endpoints is strong and durable, it can slow penetration of alternatives despite discount pressure.
3. Safety and dosing practicality
   • Real-world tolerability affects persistence and thus revenue more than marginal efficacy differences once adoption is underway.

---

How strong is the patent estate for SYFOVRE and what does it mean for revenue protection?

Revenue protection for SYFOVRE depends on (1) the composition-of-matter coverage for pegcetacoplan, (2) formulation and delivery system patents tailored to intravitreal use, and (3) method-of-use coverage tied to GA indication.

Patent estate categories that typically control exclusivity

• Composition of matter for the active ingredient and key intermediates.
• Formulation and intravitreal delivery (stability, concentration, excipients).
• Medical use patents covering dosing regimens and GA treatment.

Exclusivity is not the same as patents

Financial protection is typically a blend of:

• Regulatory exclusivity (data exclusivity and market exclusivity periods)
• Patent term (composition and use)
• Patent life tied to specific formulations and methods

(Without the specific Orange Book and listed patents for SYFOVRE in the provided input, a complete, date-by-date patent matrix cannot be produced.)

---

When does SYFOVRE lose exclusivity, and what generic entry risks exist?

Generic entry risk for intravitreal biologic-like small molecules varies by whether pegcetacoplan is protected by enforceable composition or formulation patents at the time of potential challenge.

What determines whether generic or biosimilar entry is feasible

• Whether legal barriers exist under the patent landscape
• Whether the drug is treated as a small-molecule generic framework or complex biologic-like pathway
• Whether formulation and method patents block “noninfringing” designs

Paragraph IV and litigation pathway

If there are Orange Book-listed patents, a Paragraph IV filing can trigger:

• automatic stays,
• infringement litigation, and
• potential settlement agreements.

(Exact expiration dates, settlement terms, and litigation status cannot be listed because the underlying patent and Orange Book record for SYFOVRE is not included in the input data.)

---

What is the Orange Book status of SYFOVRE and what patents are listed?

Orange Book status is the practical map of:

• which patents can be challenged,
• which listed patents tie to which NDA, and
• what exclusivity windows matter most commercially.

Data needed for an Orange Book table

A credible Orange Book summary requires:

• NDA number,
• patent list with publication and issue numbers,
• expiration dates by patent,
• and exclusivity blocks (data and other).

This information is not present in the input data, so an accurate listing cannot be produced.

---

What formulations and dosing regimens are protected for SYFOVRE?

Commercial differentiation in retinal injectables often depends on:

• concentration and fill volume,
• stability and shelf-life,
• administration technique guidance,
• and dosing schedules tied to GA lesion outcomes.

Common patent-protection patterns

• Manufacturing process patents to restrict alternate supply chains.
• Stability and storage condition patents that constrain formulation changes.
• Method-of-use regimen patents that prevent “label shift” dosing strategies.

A specific SYFOVRE protected regimens list requires the actual patent claims or listed patents tied to the NDA, which is not provided in the input data.

---

What patent litigation affects SYFOVRE’s competitive timeline?

Litigation impacts:

• launch timing of any challenger,
• whether settlement accelerates or delays entry,
• and how courts interpret claim scope.

Litigation signals to model

• filing dates for challenge(s),
• venue and case schedules,
• injunction or stay status,
• and settlement milestones.

No litigation docket details are included in the input data, so this cannot be enumerated without risking inaccuracy.

---

How does FDA regulatory status influence SYFOVRE commercialization and reimbursement?

FDA status affects commercialization via label scope and whether payers have confidence in coverage.

Commercial relevance of label scope

• Indication breadth determines eligibility and initial adoption rate.
• Dosing and monitoring instructions influence persistence and treatment scheduling.
• Safety monitoring requirements affect clinic workflow and site-of-care economics.

A specific label-driven commercialization timeline requires the exact FDA approval dates and label history, which are not included in the input data.

---

How do licensing and payer contracting strategies shape net sales for SYFOVRE?

Net revenue depends on how the company structures contracting, including:

• payer rebate agreements,
• specialty pharmacy or buy-and-bill economics,
• and patient assistance for early market penetration.

Typical contracting mechanics in specialty ophthalmology

• Formulary placement depends on budget impact
• Prior authorization criteria reduce nonconforming starts
• Renewal criteria manage long-run cost

Without deal-level disclosures or payer financial statements in the input data, only the contracting mechanisms can be described, not quantified.

---

What financial risks and upside levers determine SYFOVRE’s next 12–36 months?

Upside levers

• Improved payer authorization rates as real-world evidence accumulates
• Better persistence due to tolerability and clinic workflow
• Expanded patient pools if real-world outcomes support broader eligibility

Downside levers

• Discount escalation triggered by formulary competition
• Early persistence weakness leading to lower quarter-over-quarter starts-to-treated ratio
• Access constraints from stricter prior authorization documentation

Investment and planning risk to quantify

• Net sales sensitivity to persistence and authorization approval rate
• Effect of competitor entry on discount rate and payer mix
• Timing risk from legal challenges if patent term risk emerges

---

How does SYFOVRE compare with other GA therapies in market access dynamics?

For GA, the competitive battlefield is usually:

• speed to payer coverage,
• ease of documentation and eligibility,
• and clinic adoption friction.

Comparative factors that drive share

• Prior authorization burden
• Requisite baseline testing and lesion measurement workflow
• Adherence to monitoring schedule
• Safety profile and injection frequency demands

A drug-by-drug comparison with market share and net price requires competitor-specific financial disclosures not included in the input data.

---

Key Takeaways

• SYFOVRE’s financial trajectory is driven by chronic-use economics: patient starts and persistence under payer access constraints.
• Near-term revenue growth hinges on payer authorization speed and documentation alignment, plus clinic onboarding and persistence.
• Pricing pressure is primarily discount and authorization policy, not headline list changes.
• Competitive risk centers on GA alternatives entering with comparable or better access and discounting leverage.
• Patent and exclusivity risk cannot be quantified from the provided input because Orange Book and patent listing data are not included.

---

FAQs

1. How does prior authorization affect SYFOVRE net sales versus list price?
   Authorization approval rates and renewal criteria determine covered starts and continuation, translating to net revenue through rebates, discounts, and access rules.

2. What drives persistence risk for intravitreal GA therapies like SYFOVRE?
   Real-world tolerability, injection scheduling burden, and payer renewal policies that require benefit documentation.

3. What are the main discount levers payers use once multiple GA therapies exist?
   Contract rebates, formulary placement tied to budget impact, and tighter continuation criteria that reduce treated patient counts.

4. How do patent estates influence the timing of generic or alternative entry for SYFOVRE?
   Enforceable composition, formulation, and method-of-use patents restrict noninfringing design and delay challenge-driven entry.

5. What label elements most influence SYFOVRE payer coverage decisions?
   Indication scope, dosing regimen requirements, and monitoring needs that map to payer documentation protocols.

---

References

1. U.S. Food and Drug Administration. Orange Book and FDA label information (access required for SYFOVRE-specific listings).
2. U.S. Food and Drug Administration. FDA drug approvals and exclusivity guidance.

DrugChatter Q&A for SYFOVRE

Syfovre fda approval date?
When was syfovre approved?
Indianapolis syfovre injection?
What are the side effects of Syfovre?